Research
Hormonal
Insulin should be the first-line treatment if insulin deficiency is the predominant factor at the onset of type 2 diabetes, followed by cardio-renal protective medications.
If your body isn't making enough insulin, start with insulin therapy first. After stabilizing your blood sugar with insulin, add medications that protect your heart and kidneys (SGLT-2 inhibitors or GLP-1 receptor agonists).
GoodConditionalHIGH confidence
If insulin deficiency is the predominant factor at the outset of type 2 diabetes, the order of medications has to be reversed: insulin first and then cardio-renal protective medications (SGLT-2 inhibitors, GLP-1 receptor agonists).
Why this rating
Based on clinical guidelines and the need to address insulin deficiency directly.
Source
Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)
Giacomo Gastaldi et al. · Swiss Medical Weekly · 2023
DOI 10.57187/smw.2023.40060
clinical_guidelineCited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- If initial double combination therapy fails to control HbA1c, a triple combination of metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist is recommended as the best treatment to reduce cardiovascular events and mortality.Good
Related findings · Hormonal
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
- Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) consistently achieves sustained weight loss of 25-30% and improves cardiovascular outcomes, serving as the current gold standard for efficacy.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →